THTeruyuki Hirano

Teruyuki Hirano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Teruyuki Hirano has a total of 393 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early functional outcomes after mechanical thrombectomy in patients with large vessel occlusion and active cancer

    by Shinya Tomari, Hiroyuki Kawano, Kaoru Nakanishi, Mikito Saito, Eisaku Tsuji, Atsushi Yamamichi, Takashi Johno, Hayate Onuki, Risa Toyota, Reona Miwa, et al.

  • Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized Trial

    by John W. Eikelboom, Lizhen Xu, Ashkan Shoamanesh, Qiang Dong, Teruyuki Hirano, Jeffrey L. Saver, Jaime Masjuan, Andrew M. Demchuk, Charlotte Cordonnier, Daniel Bereczki, et al.

    BACKGROUND: OCEANIC-STROKE (XXX) showed that asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing bleeding in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack. We characterized bleeding categories, sites, and key subgroups. METHODS: In the safety population, 12 254 participants received at least 1 dose of asundexian (n=6124) or placebo (n=6130). Bleeding was categorized by International Society on Thrombosis and Haemostasis criteria as major, clinically relevant nonmajor (CRNM), or minor. While-on-treatment analyses included events through 2 days after the last dose, with death and permanent discontinuation as competing risks. RESULTS: Major bleeding occurred in 117 (1.9%) participants with asundexian and 107 (1.7%) with placebo (cause-specific hazard ratio [csHR], 1.10 [95% CI, 0.85–1.44]; P =0.46). Major or CRNM bleeding occurred in 339 (5.5%) and 307 (5.0%), respectively (csHR, 1.12 [95% CI, 0.96–1.30]; P =0.16), and any bleeding in 763 (12.5%) and 752 (12.3%) (csHR, 1.02 [95% CI, 0.93–1.13]; P =0.65). Treatment effects for major and major or CRNM bleeding were consistent across prespecified subgroups, including planned dual antiplatelet therapy. Symptomatic intracranial hemorrhage occurred in 41 (0.7%) and 36 (0.6%) participants. Any gastrointestinal bleeding occurred in 186 (3.0%) and 147 (2.4%) (csHR, 1.28 [95% CI, 1.03–1.59]), and lower gastrointestinal bleeding in 102 (1.7%) and 59 (1.0%) (csHR, 1.75 [95% CI, 1.27–2.41]), primarily rectal bleeding. Any procedure-related bleeding and any mucosal bleeding did not differ significantly. CONCLUSIONS: Asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing major, major or CRNM, or any bleeding. Lower gastrointestinal bleeding was more frequent with asundexian, whereas treatment effects on major and major or CRNM bleeding were consistent across prespecified subgroups. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05686070.

  • Open Access

    Impact of Cerebral Small Vessel Disease on Functional Decline: Bleeding With Antithrombotic Therapy 2 Study

    by Yoshito Arakaki, Kaori Miwa, Masatoshi Koga, Sohei Yoshimura, Kanta Tanaka, Jin Nakahara, Yusuke Yakushiji, Makoto Sasaki, Shigeru Fujimoto, Masayuki Shiozawa, et al.

    BACKGROUND: To what extent cerebral small vessel disease (SVD) contributes to functional disability remains unclear. We investigated the longitudinal effect of SVD burden on functional decline. METHODS: In this investigator-initiated, prospective, multicenter, and observational study, patients receiving oral antithrombotic therapy for cerebrovascular or cardiovascular diseases were enrolled from 52 hospitals across Japan (2016–2019) and followed for 24 months. SVD score (range, 0–4) was calculated on baseline magnetic resonance imaging obtained under prespecified conditions. The outcomes were an increase in modified Rankin Scale (mRS) score from baseline to end of follow-up (ΔmRS score ≥1). Logistic regression evaluated the association between ΔmRS score ≥1 and SVD score, adjusting for age, sex, premorbid mRS, vascular risk factors, antithrombotic therapy, magnetic resonance imaging field strength, and bleeding or ischemic events during follow-up. Bleeding and ischemic events were treated as time-dependent covariates. Causal mediation analyses using a 4-way decomposition separated the effects of SVD score ≥3 on ΔmRS score ≥1 into direct and indirect effects (mediated by major bleeding or ischemic events). RESULTS: Of 5378 patients enrolled, 613 were excluded mainly due to the lack of clinical or imaging data. Finally, 4765 patients were analyzed (1573 women; median age, 73 years); ΔmRS score ≥1 was observed in 13.2% of patients with SVD score 0, 16.1% with 1, 20.7% with 2, 28.1% with 3, and 28.2% with 4. SVD score of 3 (adjusted odds ratio, 1.65 [95% CI, 1.27–2.15]) and SVD score of 4 (1.62 [95% CI, 1.19–2.19]) were associated with ΔmRS score ≥1 compared with SVD score of 0. Causal mediation analysis indicated that 73.05% of the total effect of SVD score ≥3 on ΔmRS score ≥1 was attributed to the controlled direct effect (coefficient, 0.497 [95% CI, 0.26–0.73]). CONCLUSIONS: SVD burden was associated with functional decline beyond significant bleeding or ischemic events.

  • Open Access

    Sex differences in the incidence of composite ischemic and bleeding events in ischemic stroke patients with nonvalvular atrial fibrillation and atherosclerosis

    by Masahiro Morishita, Kazutaka Uchida, Shinichi Yoshimura, Shuhei Okazaki, Kanta Tanaka, Yukako Yazawa, Ryosuke Doijiri, Masatoshi Koga, Masafumi Ihara, Shiro Yamamoto, et al.

  • CT Perfusion Abnormality in Hypoglycemic Focal Neurological Deficits

    by Mikito Saito, Hiroyuki Kawano, Ayane Kawatake, Teruyuki Hirano


  • Open Access

    Prediction Model to Optimize Long-Term Antithrombotic Therapy Using Covert Vascular Brain Injury and Clinical Features

    by Kaori Miwa, Masatoshi Koga, Kanta Tanaka, Yusuke Yakushiji, Makoto Sasaki, Kohsuke Kudo, Masayuki Shiozawa, Sohei Yoshimura, Masafumi Ihara, Shigeru Fujimoto, et al.

    BACKGROUND: Defining the risk of developing major bleeding, especially intracranial hemorrhage (ICH), or ischemic stroke (IS) in patients receiving antithrombotic therapy is crucial. Existing risk prediction tools would inadequately assess the net clinical benefit of antithrombotic therapy. We aimed to develop novel risk scores incorporating covert vascular brain injury to personalize the risk assessment of major bleeding, ICH, and IS in patients receiving antithrombotic therapy. METHODS: The prospective, multicenter, observational study (BAT2 [Bleeding With Antithrombotic Therapy Study-2]) enrolled patients receiving oral antiplatelets or anticoagulants from 52 hospitals across Japan between 2016 and 2019. Multimodal brain magnetic resonance imaging was performed at baseline under prespecified conditions to determine cerebral small vessel disease (white matter hyperintensity, cerebral microbleed, lacune, enlarged perivascular space, and cortical superficial siderosis), nonlacunar infarct, and intracranial artery disease with central reading. Risk scores, collectively termed the BAT2 scores, were developed separately to evaluate the comparative risks of (1) major bleeding, (2) ICH, and (3) IS based on covariates from Cox proportional hazards models and clinical relevance. Model performance was assessed with the Harrell C-index and calibration slope adjusted for optimism via bootstrapping. RESULTS: Of 5378 patients enrolled, 5250 were analyzed (mean age, 71±11 years, 33% women); 93 experienced major bleeding, including 55 had ICH, and 197 had IS during a median follow-up of 2.0 years. Predictors for bleeding included age, underweight, renal impairment, hypertension, cerebral microbleed, lacune, and antithrombotic treatment type. Predictors for ICH further included deep white matter hyperintensity but not renal impairment. For IS, predictors included age, renal impairment, diabetes, atrial fibrillation, lacune, cerebral microbleed, nonlacunar infarct, and intracranial artery disease. Prediction performance showed optimism-adjusted C-index and calibration slope of 0.69 (95% CI, 0.64–0.74) and 0.82 (95% CI, 0.62–1.06) for bleeding, 0.75 (95% CI, 0.67–0.80) and 0.80 (95% CI, 0.56–1.02) for ICH, and 0.64 (95% CI, 0.60–0.68) and 0.92 (95% CI, 0.73–1.18) for IS. CONCLUSIONS: The BAT2 scores may help optimize the balance between risks and benefits of antithrombotic therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02889653. URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000023669.


  • Asia Pacific Stroke Conference 2025, Kobe, Japan, September 13–15, 2025, on Advancing Stroke Care: Global and Local Challenges – Introduction

    by Teruyuki Hirano, Manabu Shirakawa, Shinichi Yoshimura, Wing Chi Fong, Narayanaswamy Venketasubramanian


  • STAY-HOME: Endovascular Thrombectomy for Patients With Prestroke Disability

    by Jason Vuong, Thanh G. Phan, Bernard Yan, Peter J. Mitchell, Stephen M. Davis, Masatoshi Koga, Kazunori Toyoda, Teruyuki Hirano, Shinichi Yoshimura, Henry Ma

    Thrombectomy significantly improves clinical outcomes in patients with large vessel occlusion. However, the foundational trials used restrictive criteria, excluding patients with prestroke disability and included a few elderly patients (>80 years old). In addition, results from registries demonstrated conflicting results. We propose that there is equipoise for the elderly and prestroke disability to undergo thrombectomy and that trials are urgently required to guide treatment.


  • Open Access

    Effects of Prone Posture Maneuver to Ameliorate Pusher Behavior in Acute Stroke: A Retrospective Study

    by Mitsuyo Ikeda, Syoichi Tashiro, Yusuke Harada, Kohei Ishita, Akifumi Masuda, Teruyuki Hirano, Shin Yamada

    Background: Pusher behavior after stroke is an important sequela that interferes with rehabilitation and independence in activities of daily living. As represented by visual or vestibular feedback, conventional methods require substantial assistance and time commitments, but have limited effectiveness. A recent case series suggests that prone posture may alleviate pusher behavior in patients with acute stroke. This study was conducted to retrospectively investigate the effects of prone posture maneuvers. Methods: This retrospective cross-sectional observational study was conducted in a stroke care unit at a university hospital. In total, 37 acute stroke cases presenting with pusher behavior were included from 787 eligible patients. Individuals with pusher behavior were conditioned with prone posturing for 10 min for 2 consecutive days, in addition to regular daily rehabilitation training. The Scale for Contraversive Pushing (SCP) values, Stroke Impairment Assessment Set (SIAS), and functional activities were assessed before, immediately after, and three days after the intervention. Results: The SCP value and the ability to roll over and sit balanced significantly improved compared with the baseline (p < 0.05) and persisted for 3 days after the intervention. Multiple regression analysis identified the SIAS motor score as a determinant of SCP changes. Conclusions: The prone posture maneuver promptly and consistently suppressed pusher behavior, particularly in patients with mild paresis, as indicated by SCP values in acute stroke cases. The uncontrolled, single-site, and retrospective features of the current study require further investigation.


  • Open Access

    Global Results of Implantable Loop Recorder for Detection of Atrial Fibrillation After Stroke: Reveal LINQ Registry

    by Kazunori Toyoda, Kengo Kusano, Yasuyuki Iguchi, Takanori Ikeda, Itsuro Morishima, Hirofumi Tomita, Taku Asano, Teiichi Yamane, Ichiro Nakahara, Eiichi Watanabe, et al.

    Background: We aimed to quantify the incidence of atrial fibrillation (AF) in patients with cryptogenic stroke globally, as well as separately in patients in and outside of Japan, using an implantable loop recorder from a prospective, observational, Reveal LINQ Registry. Methods and Results: Patients developing cryptogenic stroke and monitored by implantable loop recorder for searching AF were studied. The primary end point was incidence of AF within 36 months after insertion. Secondary end points were recurrent ischemic stroke/transient ischemic attack and AF‐related treatment strategies. A total of 271 patients (61.6±14.3 years, 170 men, 60 from Japan) were enrolled from 12 countries. AF was detected in 28.2% at 36 months. The median time from enrollment to AF detection was 7.9 months. During the first 12 months, the AF detection rate slope was relatively steeper in the Japanese subgroup versus non‐Japanese patients. However, by 3 years, the cumulative incidence of AF detection did not differ between groups. Age was the only variable associated with AF detection (hazard ratio, 1.05 [95% CI, 1.02–1.07] per year), trending higher in older age groups. Of the 271 patients, 11 (4.1%) developed recurrent ischemic stroke/transient ischemic attack; AF was detected by implantable loop recorder in only 1 of these patients. Patients with detected AF were more commonly taking oral anticoagulation than those without AF at the last follow‐up (64.7% versus 25.3%, P <0.001). Conclusions: The rate of AF detection was similar to other studies in stroke populations monitored by implantable loop recorders, including CRYSTAL‐AF (Cryptogenic Stroke and Underlying Atrial Fibrillation), STROKE‐AF (Stroke of Unknown Cause and Underlying Atrial Fibrillation) and PER‐DIEM (Post‐Embolic Rhythm Detection With Implantable Versus External Monitoring). Patients with detected AF more commonly initiated anticoagulation than those without AF.